{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T01:45:32Z","timestamp":1790905532802,"version":"4.1.0"},"reference-count":57,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2003,10,1]],"date-time":"2003-10-01T00:00:00Z","timestamp":1064966400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2003,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Learning Objectives<\/jats:title>\n                  <jats:p>After completing this course, the reader will be able to:<\/jats:p>\n                  <jats:p>Identify appropriate candidates for consideration of genetic testing for mutations in BRCA1 or BRCA2. Explain the importance of appropriate patient counseling prior to proceeding with genetic testing for mutations in BRCA1 or BRCA2, including genetic counseling and education regarding interpretation and implications of test results. Discuss risk management options for BRCA mutation carriers and the available evidence regarding their effectiveness.<\/jats:p>\n                  <jats:p>Access and take the CME test online and receive one hour of AMA PRA category 1 credit at CME.TheOncologist.com<\/jats:p>\n                  <jats:p>It is estimated that 5%\u201310% of all breast cancers in women are associated with hereditary susceptibility due to mutations in autosomal dominant genes, such as BRCA1 and BRCA2, p53, pTEN, and STK11\/LKB1. Another 15%\u201320% of female breast cancers occur in women with a family history but without an apparent autosomal dominant inheritance pattern, and are probably due to other genetic factors with environmental influence. Approximately 7%\u201310% of ovarian cancers occur in women with hereditary susceptibility, primarily secondary to mutations in BRCA1 and BRCA2, with smaller contributions from mutations in mismatch repair genes associated with the hereditary nonpolyposis colorectal cancer and other, as yet undiscovered, genes.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1634\/theoncologist.8-5-466","type":"journal-article","created":{"date-parts":[[2004,8,24]],"date-time":"2004-08-24T21:38:39Z","timestamp":1093383519000},"page":"466-473","source":"Crossref","is-referenced-by-count":25,"title":["Genetics and the Management of Women at High Risk for Breast Cancer"],"prefix":"10.1093","volume":"8","author":[{"given":"Betty A.","family":"Mincey","sequence":"first","affiliation":[{"name":"Mayo Clinic, Jacksonville, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2003,10,1]]},"reference":[{"key":"2021122209451981200_R1","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/S0140-6736(01)06524-2","article-title":"Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast cancer and 101,986 women without the disease","volume":"358","author":"Collaborative Group on Hormonal Factors in Breast Cancer","year":"2001","journal-title":"Lancet"},{"key":"2021122209451981200_R2","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1002\/(SICI)1097-0142(19960601)77:11<2318::AID-CNCR21>3.0.CO;2-Z","article-title":"The genetic attributable risk of breast and ovarian cancer","volume":"77","author":"Claus","year":"1996","journal-title":"Cancer"},{"key":"2021122209451981200_R3","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1001\/jama.1993.03510130069033","article-title":"A comprehensive evaluation of family history and breast cancer risk. The Utah Population Database","volume":"270","author":"Slattery","year":"1993","journal-title":"JAMA"},{"key":"2021122209451981200_R4","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1093\/oxfordjournals.aje.a115616","article-title":"Age at onset as an indicator of familial risk of breast cancer","volume":"131","author":"Claus","year":"1990","journal-title":"Am J Epidemiol"},{"key":"2021122209451981200_R5","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1086\/301749","article-title":"Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium","volume":"62","author":"Ford","year":"1998","journal-title":"Am J Hum Genet"},{"key":"2021122209451981200_R6","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1093\/jnci\/92.14.1126","article-title":"Genetic and hormonal risk factors in breast cancer","volume":"92","author":"Martin","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"2021122209451981200_R7","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1093\/jnci\/93.2.121","article-title":"Cancer in patients with ataxia-telangiectasia and in their relatives in nordic countries","volume":"93","author":"Olsen","year":"2001","journal-title":"J Natl Cancer Inst"},{"key":"2021122209451981200_R8","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1002\/1097-0142(20010801)92:3<479::AID-CNCR1346>3.0.CO;2-G","article-title":"Increased frequencey of ATM mutations in breast carcinoma patients with early onset disease and positive family history","volume":"92","author":"Teraoka","year":"2001","journal-title":"Cancer"},{"key":"2021122209451981200_R9","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1038\/sj.bjc.6600637","article-title":"CHEK2 variants in susceptibility to breast cancer and evidence of retention of the wild type allele in tumours","volume":"87","author":"Sodha","year":"2002","journal-title":"Br J Cancer"},{"key":"2021122209451981200_R10","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/ng879","article-title":"Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations","volume":"31","author":"Meijers-Heijboer","year":"2002","journal-title":"Nat Genet"},{"key":"2021122209451981200_R11","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0092-8674(02)00615-3","article-title":"Cancer susceptibility and the functions of BRCA1 and BRCA2","volume":"108","author":"Venkitaraman","year":"2002","journal-title":"Cell"},{"key":"2021122209451981200_R12","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1086\/302320","article-title":"The prevalence of common BRCA1 and BRCA2 mutations among Ashkenazi Jews","volume":"64","author":"Hartge","year":"1999","journal-title":"Am J Hum Genet"},{"key":"2021122209451981200_R13","first-page":"1457","article-title":"Estimates of the gene frequency of BRCA1 and its contribution to breast and ovarian cancer incidence","volume":"57","author":"Ford","year":"1995","journal-title":"Am J Hum Genet"},{"key":"2021122209451981200_R14","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1200\/JCO.2002.20.6.1480","article-title":"Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals","volume":"20","author":"Frank","year":"2002","journal-title":"J Clin Oncol"},{"key":"2021122209451981200_R15","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1001\/jama.1995.03520310033026","article-title":"A collaborative survey of 80 mutations in the BRCA1 breast and ovarian cancer susceptibility gene. Implications for presymptomatic testing and screening","volume":"273","author":"Shattuck-Eidens","year":"1995","journal-title":"JAMA"},{"key":"2021122209451981200_R16","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1086\/318787","article-title":"Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer","volume":"68","author":"Risch","year":"2001","journal-title":"Am J Hum Genet"},{"key":"2021122209451981200_R17","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/S0140-6736(94)91578-4","article-title":"Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium","volume":"343","author":"Ford","year":"1994","journal-title":"Lancet"},{"key":"2021122209451981200_R18","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1086\/513891","article-title":"Cancer risks in two large breast cancer families linked to BRCA2 on chromosome 13q12-13","volume":"61","author":"Easton","year":"1997","journal-title":"Am J Hum Genet"},{"key":"2021122209451981200_R19","first-page":"467","article-title":"The lifetime risks of breast cancer in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations","volume":"10","author":"Satagopan","year":"2001","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2021122209451981200_R20","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1056\/NEJM199705153362001","article-title":"The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews","volume":"336","author":"Struewing","year":"1997","journal-title":"N Engl J Med"},{"key":"2021122209451981200_R21","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1093\/jnci\/91.15.1310","article-title":"Cancer risks in BRCA2 mutation carriers","volume":"91","author":"Breast Cancer Linkage Consortium","year":"1999","journal-title":"J Natl Cancer Inst"},{"key":"2021122209451981200_R22","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1016\/S0140-6736(02)08434-9","article-title":"Outcome of conservatively managed early-onset breast cancer by BRCA1\/2 status","volume":"359","author":"Haffty","year":"2002","journal-title":"Lancet"},{"key":"2021122209451981200_R23","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1200\/JCO.2000.18.19.3360","article-title":"Effect of radiotherapy after breast-conserving treatment in women with breast cancer and germline BRCA1\/2 mutations","volume":"18","author":"Pierce","year":"2000","journal-title":"J Clin Oncol"},{"key":"2021122209451981200_R24","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1200\/JCO.1998.16.5.1642","article-title":"BRCA-associated breast cancer in young women","volume":"16","author":"Robson","year":"1998","journal-title":"J Clin Oncol"},{"key":"2021122209451981200_R25","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1200\/JCO.1998.16.7.2417","article-title":"Sequence analysis of BRCA1 and BRCA2: correlation of mutations with family history and ovarian cancer risk","volume":"16","author":"Frank","year":"1998","journal-title":"J Clin Oncol"},{"key":"2021122209451981200_R26","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1056\/NEJM199705153362002","article-title":"BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer","volume":"336","author":"Couch","year":"1997","journal-title":"N Engl J Med"},{"key":"2021122209451981200_R27","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1001\/jama.1997.03550150046034","article-title":"BRCA1 sequence analysis in women at high risk for susceptibility mutations. Risk factor analysis and implications for genetic testing","volume":"278","author":"Shattuck-Eidens","year":"1997","journal-title":"JAMA"},{"key":"2021122209451981200_R28","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1093\/jnci\/89.3.227","article-title":"Probability of carrying a mutation of breast-ovarian cancer gene BRCA1 based on family history","volume":"89","author":"Berry","year":"1997","journal-title":"J Natl Cancer Inst"},{"key":"2021122209451981200_R29","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1086\/301670","article-title":"Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2","volume":"62","author":"Parmigiani","year":"1998","journal-title":"Am J Hum Genet"},{"key":"2021122209451981200_R30","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1001\/jama.1997.03540420063031","article-title":"Genetic testing for susceptibility to adult-onset cancer. The process and content of informed consent","volume":"277","author":"Geller","year":"1997","journal-title":"JAMA"},{"key":"2021122209451981200_R31","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1086\/303076","article-title":"Screening for genomic rearrangements in families with breast and ovarian cancer identifies BRCA1 mutations previously missed by conformation-sensitive gel electrophoresis or sequencing","volume":"67","author":"Unger","year":"2000","journal-title":"Am J Hum Genet"},{"key":"2021122209451981200_R32","doi-asserted-by":"crossref","first-page":"6841","DOI":"10.1038\/sj.onc.1205685","article-title":"Significant contribution of large BRCA1 gene rearrangements in 120 French breast and ovarian cancer families","volume":"21","author":"Gad","year":"2002","journal-title":"Oncogene"},{"key":"2021122209451981200_R33","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1001\/jama.1997.03540360065034","article-title":"Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. Cancer Genetics Studies Consortium","volume":"277","author":"Burke","year":"1997","journal-title":"JAMA"},{"key":"2021122209451981200_R34","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1200\/JCO.2002.20.5.1260","article-title":"Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers","volume":"20","author":"Scheuer","year":"2002","journal-title":"J Clin Oncol"},{"key":"2021122209451981200_R35","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1148\/radiology.215.1.r00ap01267","article-title":"Breast MR imaging screening in 192 women proved or suspected to be carriers of a breast cancer susceptibility gene: preliminary results","volume":"215","author":"Kuhl","year":"2000","journal-title":"Radiology"},{"key":"2021122209451981200_R36","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1093\/jnci\/93.14.1095","article-title":"Magnetic resonance imaging and mammography in women with a hereditary risk of breast cancer","volume":"93","author":"Stoutjesdijk","year":"2001","journal-title":"J Natl Cancer Inst"},{"key":"2021122209451981200_R37","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1056\/NEJM199901143400201","article-title":"Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer","volume":"340","author":"Hartmann","year":"1999","journal-title":"N Engl J Med"},{"key":"2021122209451981200_R38","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/ijc.10666","article-title":"A BRCA1\/2mutation, high breast density and prominent pushing margins of a tumor independently contribute to a frequent false-negative mammography","volume":"102","author":"Tilanus-Linthorst","year":"2002","journal-title":"Int J Cancer"},{"key":"2021122209451981200_R39","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1056\/NEJM200107193450301","article-title":"Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation","volume":"345","author":"Meijers-Heijboer","year":"2001","journal-title":"N Engl J Med"},{"key":"2021122209451981200_R40","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1056\/NEJM199705153362022","article-title":"Decision analysis\u2014effects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 or BRCA2 mutations","volume":"336","author":"Schrag","year":"1997","journal-title":"N Engl J Med"},{"key":"2021122209451981200_R41","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.1002\/1097-0142(19930501)71:9<2751::AID-CNCR2820710911>3.0.CO;2-J","article-title":"Primary peritoneal carcinoma after prophylactic oophorectomy in women with a family history of ovarian cancer. A report of the Gilda Radner Familial Ovarian Cancer Registry","volume":"71","author":"Piver","year":"1993","journal-title":"Cancer"},{"key":"2021122209451981200_R42","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa020119","article-title":"Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation","volume":"346","author":"Kauff","year":"2002","journal-title":"N Engl J Med"},{"key":"2021122209451981200_R43","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1056\/NEJMoa012158","article-title":"Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations","volume":"346","author":"Rebbeck","year":"2002","journal-title":"N Engl J Med"},{"key":"2021122209451981200_R44","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1093\/jnci\/91.17.1475","article-title":"Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers","volume":"91","author":"Rebbeck","year":"1999","journal-title":"J Natl Cancer Inst"},{"key":"2021122209451981200_R45","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1093\/jnci\/90.18.1371","article-title":"Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study","volume":"90","author":"Fisher","year":"1998","journal-title":"J Natl Cancer Inst"},{"key":"2021122209451981200_R46","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/S0140-6736(98)85012-5","article-title":"Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial","volume":"352","author":"Powles","year":"1998","journal-title":"Lancet"},{"key":"2021122209451981200_R47","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S0140-6736(98)04394-3","article-title":"Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Italian Prevention Study","volume":"352","author":"Veronesi","year":"1998","journal-title":"Lancet"},{"key":"2021122209451981200_R48","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S0140-6736(02)09962-2","article-title":"First results from the International Breast Cancer Intervention Study (IBIS-1): a randomised prevention trial","volume":"360","author":"Cuzick","year":"2002","journal-title":"Lancet"},{"key":"2021122209451981200_R49","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/S0140-6736(03)12342-2","article-title":"Overview of the main outcomes in breast-cancer prevention trials","volume":"361","author":"Cuzick","year":"2003","journal-title":"Lancet"},{"key":"2021122209451981200_R50","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1001\/jama.286.18.2251","article-title":"Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial","volume":"286","author":"King","year":"2001","journal-title":"JAMA"},{"key":"2021122209451981200_R51","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1016\/S0140-6736(00)03258-X","article-title":"Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group","volume":"356","author":"Narod","year":"2000","journal-title":"Lancet"},{"key":"2021122209451981200_R52","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1200\/JCO.2003.09.052","article-title":"Use of genetic testing and prophylactic mastectomy and oophorectomy in women with breast or ovarian cancer from families with a BRCA1 or BRCA2 mutation","volume":"21","author":"Meijers-Heijboer","year":"2003","journal-title":"J Clin Oncol"},{"key":"2021122209451981200_R53","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1056\/NEJMoa013202","article-title":"Oral contraceptives and the risk of breast cancer","volume":"346","author":"Marchbanks","year":"2002","journal-title":"N Engl J Med"},{"key":"2021122209451981200_R54","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1016\/S0140-6736(96)90806-5","article-title":"Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53,297 women with breast cancer and 100,239 women without breast cancer from 54 epidemiological studies","volume":"347","year":"1996","journal-title":"Lancet"},{"key":"2021122209451981200_R55","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1001\/jama.284.14.1791","article-title":"Risk of breast cancer with oral contraceptive use in women with a family history of breast cancer","volume":"284","author":"Grabrick","year":"2000","journal-title":"JAMA"},{"key":"2021122209451981200_R56","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1093\/jnci\/94.23.1773","article-title":"Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers","volume":"94","author":"Narod","year":"2002","journal-title":"J Natl Cancer Inst"},{"key":"2021122209451981200_R57","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1001\/jama.288.3.321","article-title":"Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial","volume":"288","author":"Rossouw","year":"2002","journal-title":"JAMA"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.8-5-466","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.8-5-466","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/8\/5\/466\/41840163\/oncolo_8_5_466.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/8\/5\/466\/41840163\/oncolo_8_5_466.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,22]],"date-time":"2021-12-22T17:14:13Z","timestamp":1640193253000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/8\/5\/466\/6387549"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,10,1]]},"references-count":57,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2003,10,1]]},"published-print":{"date-parts":[[2003,10,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.8-5-466","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2003,10,1]]},"published":{"date-parts":[[2003,10,1]]}}}